Avastin plus R-CHOP trial for DLBCL halted for safety reasons


An independent safety monitoring board has recommended that Roche, makers of Avastin, stop enrolling patients in a phase III trial that had been designed to test the safety and efficacy of adding Avastin to R-CHOP for the treatment of patients with diffuse large B-cell lymphoma (DLBCL).

The recommendation was made after initial data from 720 patients indicated that the benefits did not outweigh the risks.

Avastin remains Roche's biggest selling cancer drug despite this, and despite the fact that the drug failed to provide any benefits in previous trials to patients with gastric and prostate cancers.

Nonetheless, the drug is FDA approved in various combinations for metastatic colorectal cancer, non-small cell lung cancer, metastatic breast cancer, metastatic kidney cancer, and glioblastoma.

By Ross Bonander

LymphomaInfo Social